AzTrials
AzTrials

CholedocholithiasisNCT06676241

One-stage and Delayed Laparoscopic Cholecystectomy After Endoscopic Retrograde Cholangiopancreatography with Endoscopic Sphincterotomy in Cholecystocholedocholithiasis

An observational study of Choledocholithiasis and Cholecystolithiasis, run by Moscow Regional Research and Clinical Institute (MONIKI) at 1 site in Russia.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

In this study, it is planned to compare ERCP with ES + delayed LC in children, with one-stage LC + ERCP with ES in adults to confirm that ERCP with ES + delayed LC is more suitable for pediatric patients with cholecystocholedocholithiasis. Read more about this study

Who is it for?
Ages 0 to 80 years
What is being tested?
endoscopic retrograde cholangiopancreatography; laparoscopic cholecystectomy and endoscopic retrograde cholangiopancreatography;laparoscopic cholecystectomy
Type of treatment
Surgery or procedure
How many people
44 participants
Where
1 siteRussia
Study dates
13 Nov 2024to 5 Mar 2025
Phase
Observational
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 0 to 80 years
  • All sexes
  • No healthy volunteers
  • Child, Adult, Older adult

Study population: Moscow Regional Scientific Research Clinical Institute named after M.F. Vladimirsky

Who may be able to join

  • Informed consent from the patient, child or legal representative
  • Age 0-80 years
  • Acute cholecystitis
  • Choledocholithiasis
  • Intraoperative ERCP
  • Preoperative ERCP followed by cholecystectomy

Who cannot join

  • Unwillingness or inability to consent to the study
  • Pregnancy
  • Age > 80 years
  • Previous ERCP or percutaneous transhepatic biliary drainage
  • Anastomosis in the upper gastrointestinal tract
  • Benign or malignant stricture
Show all 11Show fewer
  • Preoperative comorbidities: gastrointestinal bleeding, severe liver disease, acute and chronic cholangitis, other known cholestatic hepatopancreatobiliary disease, septic shock.
  • In combination with Mirizzi syndrome and intrahepatic bile duct stones
  • Congenital anomaly of the biliary tract
  • Malignant neoplasms
  • Acute pancreatitis

Trial locations and contacts

1 site in 1 country.

Russia1 site
  • Moscow Regional Scientific Research Clinical Institute named after M.F. Vladimirsky

    Moscow, Moscow Oblast, 142636

Other trials in Russia

About this study

In this study, it is planned to compare ERCP with ES + delayed LC in children, with one-stage LC + ERCP with ES in adults to confirm that ERCP with ES + delayed LC is more suitable for pediatric patients with cholecystocholedocholithiasis.

Read the detailed description

Nowadays there is no gold standard for the treatment of choledocholithiasis combined with cholecystolithiasis in the pediatric population. The most common method for resolving the biliary obstruction is endoscopic retrograde cholangiopancreatography (ERCP) with endoscopic sphincterotomy (EST) and laparoscopic cholecystectomy (LC). In the adult practice, the approaches to the treatment of choledocholithiasis include the following items: laparoscopic common bile duct exploration (LCBDE), laparoendoscopic rendezvous method (LERV) and LC after ERCP. Both LCBDE and LERV allow for the simultaneous treatment of cholecystocholedocholithiasis. However, a great number of medical institutions do not have an opportunity to use these methods due to the difficulties of implementation and the need for special training and experience of specialists. The timing of LC after ERCP in patients with cholecystocholedocholithiasis also remains a subject of debate. Numerous studies recommend early LC after ERCP. However, there are high risks of injury to the common bile duct and hepatic vessels against the background of acute inflammatory process in the area of hepatoduodenal ligament. In this study, it is planned to compare ERCP with ES + delayed LC in children, with one-stage LC + ERCP with ES in adults to confirm that ERCP with ES + delayed LC is more suitable for pediatric patients with cholecystocholedocholithiasis.

The aim of this study is to evaluate the efficacy and safety of endoscopic retrograde cholangiopancreatography, endoscopic sphincterotomy with delayed laparoscopic cholecystectomy in children with cholecystocholedocholithiasis compared with one-stage cholangiopancreatography, endoscopic sphincterotomy and laparoscopic cholecystectomy in adults with cholecystocholedocholithiasis.

Being tested
endoscopic retrograde cholangiopancreatography; laparoscopic cholecystectomy, endoscopic retrograde cholangiopancreatography;laparoscopic cholecystectomy
Keywords
Сholedocholelysis, Endoscopic retrograde cholangiopancreatography (ERCP)
Medical subject headings
Choledocholithiasis, Cholecystolithiasis, Pancreatitis, Gallstones

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • endoscopic retrograde cholangiopancreatography; laparoscopic cholecystectomyProcedure or surgery

    Also called Cholangiopancreatography, Laparoscopic

    Initially, ERCP with EST was performed by an endoscopist with the consent of the patient or legal representative. The patients underwent endoscopic procedures using fluoroscopy in the operating room, under general anesthesia. Subsequently, laparoscopic cholecystectomy was performed immediately after ERCP with ES under general anesthesia.

  • endoscopic retrograde cholangiopancreatography;laparoscopic cholecystectomyProcedure or surgery

    Also called Cholangiopancreatography, Laparoscopic

    Initially, ERCP with EST was performed by an endoscopist with the consent of the patient or legal representative. The patient underwent the endoscopic procedure using fluoroscopy in the operating room, under general anesthesia. Subsequently, laparoscopic cholecystectomy was performed on a delayed basis no earlier than 7 days after ERCP

Study groups in NCT06676241
Study groupRoleWhat they receive
ERCP, EST and simultaneous LCPatients aged 10-80 years initially underwent ERCP with ES by an endoscopist with the consent of the patient or legal representative. Patients underwent endoscopic procedures using fluoroscopy in the operating room, under general anesthesia. Laparoscopic cholecystectomy was performed immediately after ERCP with ES under general anesthesia
Receives: Procedure: endoscopic retrograde cholangiopancreatography; laparoscopic cholecystectomy
ERCP, EST and LC in a delayed mannerPatients aged 0-17 years initially underwent ERCP with ES by an endoscopist with the consent of the patient or legal representative. Patients underwent endoscopic procedures using fluoroscopy in the operating room, under general anesthesia. Laparoscopic cholecystectomy was performed in a delayed manner, not earlier than 7 days after ERCP
Receives: Procedure: endoscopic retrograde cholangiopancreatography;laparoscopic cholecystectomy

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Recurrence of stones in the common bile duct

    The diagnosis of the stone in the common bile duct.

    Measured: 30 days after ERCP

Secondary outcomes (10)
  1. Bleeding

    decreased hemoglobin level, visual picture during endoscopic examination, positive stool for occult blood

    Measured: 30 days after ERCP

  2. Perforation

    by CT, radiography (fluid or gas in the retroperitoneal space or abdominal cavity, visual picture during endoscopic examination)

    Measured: 30 days after ERCP

  3. Bile leak

    bile aspirated from the abdominal cavity

    Measured: 30 days after ERCP

  4. Acute cholangitis

    intermittent chills, fever, increased proinflammatory blood markers after ERCP

    Measured: 60 days after ERCP

  5. Bile duct stricture

    after ERCP

    Measured: 1 year after ERCP

  6. Time spent in hospital until discharge

    Measured: from admission to hospital until the end of treatment (up to 8 weeks)

  7. Technical success - success of the procedures as documented by a yes or no

    Measured: 1 month

  8. Duration of the laparoscopic cholecystectomy,min

    Measured: From enrollment to the end of treatment (3 month)

  9. Acute pancreatitis

    at least two out of three criteria according to the classification developed by the INSPPIRE group

    Measured: within 14 days after ERCP

  10. Duration of the Endoscopic retrograde cholangiopancreatography

    Measured: From enrollment to the end of treatment (3 month)

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted6 Nov 2024
  2. Study start13 Nov 2024
  3. Primary completion20 Feb 2025
  4. Study completion5 Mar 2025

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Cohort
Time perspective
Retrospective
Enrolment
44 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT06676241
Sponsor's protocol ID
16/17.10.2024
Status last verified
Mar 2025
First submitted
27 Oct 2024
Last updated
10 Mar 2025
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
Yes: A complete dataset can be provided upon reasoned request

Questions about this trial

What is this clinical trial studying?

An observational study of Choledocholithiasis and Cholecystolithiasis, run by Moscow Regional Research and Clinical Institute (MONIKI) at 1 site in Russia.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 6 inclusion and 11 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 10 Mar 2025. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Russia. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Recurrence of stones in the common bile duct (time frame: 30 days after ERCP). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 10 Mar 2025.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in